Plain-English translation of NCT04047953 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether Paclitaxel (albumin-bound) combined with two other chemotherapy drugs—Oxaliplatin and S-1—can shrink advanced stomach cancer tumors. The goal is to shrink the cancer enough that surgery becomes possible for patients whose cancers are currently too large or widespread to operate on. This approach is called 'conversion therapy' because doctors hope the medication will convert an inoperable cancer into one that can be surgically removed.
Many patients with advanced stomach cancer cannot have surgery right away because their tumors are too large or have spread too far. Doctors hope that this combination of medications can shrink the cancer first, giving more patients the chance to have surgery—which offers the best long-term outcome for stomach cancer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the three-drug chemotherapy combination on a regular schedule over several months. Your doctor will monitor you closely with blood tests, scans, and physical exams to see how well the treatment is working and to watch for side effects. If the medication successfully shrinks your cancer, your surgical team will plan an operation to remove the remaining tumor. The entire process typically takes several months from start to finish.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China